To understand why cancer vaccine-induced T cells often do not eradicate tumors, we studied immune responses in mice vaccinated with gp100 melanoma peptide in incomplete Freund's adjuvant (peptide/IFA), which is commonly used in clinical cancer vaccine trials. Peptide/IFA vaccination primed tumor-specific CD8 + T cells, which accumulated not in tumors but rather at the persisting, antigen-rich vaccination site. Once there, primed T cells became dysfunctional and underwent antigen-driven, interferon-g (IFN-g)-and Fas ligand (FasL)-mediated apoptosis, resulting in hyporesponsiveness to subsequent vaccination. Provision of CD40-specific antibody, Toll-like receptor 7 (TLR7) agonist and interleukin-2 (IL-2) reduced T cell apoptosis but did not prevent vaccination-site sequestration. A nonpersisting vaccine formulation shifted T cell localization toward tumors, inducing superior antitumor activity while reducing systemic T cell dysfunction and promoting memory formation. These data show that persisting vaccine depots can induce specific T cell sequestration, dysfunction and deletion at vaccination sites; short-lived formulations may overcome these limitations and result in greater therapeutic efficacy of peptide-based cancer vaccines. npg
Cancer vaccines have shown objective therapeutic benefit in several recent randomized clinical trials [1] [2] [3] [4] [5] , but a pressing question remains why many vaccinated patients show increased numbers of circulating tumor-specific T cells without tumor regression 6 . Many clinical trials have used short, minimal determinant peptides formulated in IFA to induce tumor-specific T cell responses in patients with cancer. Typically, antigen-specific T cell responses were induced; however, objective antitumor responses have been rare 7 . A recent prospective randomized multicenter phase 3 trial showed that vaccination of patients with melanoma with a melanocyte differentiation antigenderived gp100 peptide emulsified in IFA doubled the objective response rate to high-dose IL-2 therapy and increased progressionfree survival; however, increased gp100-specific CD8 + T cell responses in peripheral blood did not necessarily cause tumor shrinkage 1 .
Whereas many mechanisms of immune regulation, suppression and escape can permit tumor growth despite tumor-specific CD8 + T cell responses 8, 9 , it is also possible that IFA-based cancer vaccines have inherent properties that limit their clinical efficacy. IFA-based vaccines are water-in-oil emulsions of antigen in mineral oil with mannide monooleate as a surfactant 10 . IFA is thought to induce local inflammation and form a depot that protects antigen from degradation and slowly releases it to antigen presenting cells (APCs) 11, 12 . Vaccination of mice with synthetic major histocompatibility complex (MHC) class I-restricted minimal determinant peptides in IFA often stimulates CD8 + T cell responses but sometimes inhibits them 13, 14 , possibly due to systemic peptide presentation by nonprofessional APCs (that is, cells that lack effective antigen presentation capacity) [13] [14] [15] . Overall, CD8 + T cell responses after peptide/IFA vaccination are poorly understood, yet 98 federally registered clinical trials of IFA-based cancer vaccines have been completed in the United States alone, and 37 additional trials are currently actively enrolling patients with cancer (ClinicalTrials.gov). Here we used a preclinical model to better understand melanoma-specific CD8 + T cell immune responses after gp100/IFA vaccination.
RESULTS

IFA-based vaccination induces T cell hyporesponsiveness
To study the fate of melanoma-specific CD8 + T cells after peptide vaccination, we tracked T cell receptor (TCR)-transgenic pmel-1 T cells in mice vaccinated with heteroclitic gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] peptide emulsified in IFA (gp100/IFA) [16] [17] [18] . Although gp100/IFA induced significant expansion of pmel-1 T cells, they dropped to near-undetectable amounts by 3 weeks and did not rebound after viral boosting with vesicular stomatitis virus encoding the gp100 melanoma antigen (VSV.gp100) ( Fig. 1a) . Vaccination with VSV.gp100 and gp100/IFA induced similar peak amounts of pmel-1 T cells, but whereas VSV.gp100-induced pmel-1 T cell responses persisted, gp100/IFA-induced responses fell precipitously and did not result in substantial memory (Fig. 1b) Combination immunization with VSV.gp100 and gp100/IFA induced similarly short-lived T cell responses, suggesting that peptide/IFA vaccination dominantly destroyed long-lived CD8 + T cell immunity. Indeed, even 30 d after VSV.gp100 vaccination, gp100/IFA vaccination resulted in brief pmel-1 T cell expansion followed by substantial termination of established T cell memory ( Fig. 1b and Supplementary Fig. 1 ). We observed similar responses after peptide/IFA vaccination for endogenous CD8 + T cells specific for chicken ovalbumin OVA 257-264 ( Fig. 1c) and OVA 257-264 -specific OT-I T cells ( Supplementary Fig. 2a ) 15, 19 , as well as for OT-II CD4 + T cells after OVA 323-339 peptide vaccination ( Supplementary Fig. 2b ), suggesting vaccination-induced hyporesponsiveness was not a peculiarity of the gp100 peptide or of pmel-1 T cells. We found no optimal dose of antigen that primed T cells without subsequent hyporesponsiveness; the lowest dose of gp100 peptide that could induce pmel-1 T cell priming (10 µg) still induced subsequent hyporesponsiveness, arguing against the mechanism of classical high-zone tolerance whereby T cell nonresponsiveness is a result of exposure to overwhelming doses of antigen ( Supplementary Fig. 3 ) 20, 21 . CD11c + dendritic cells and CD19 + B cells in the vaccine-draining lymph node (VdLN) presented gp100 peptide, as has been previously reported for OVA peptide 15, 20 (Supplementary Fig. 4a) . B cell-deficient IgH knockout and CD4 knockout mice were not protected from gp100/IFA-induced hyporesponsiveness ( Supplementary  Fig. 4b) , indicating that B cells and CD4 + regulatory T cells were not major mediators of gp100/IFA-induced hyporesponsiveness.
Persistent antigen presentation drives T cell accumulation
To extend our analysis of vaccination-induced T cells beyond the blood compartment, we visualized luciferase gene-transduced pmel-1 effector T cells 22 transferred to vaccinated mice bearing gp100-expressing B16 melanoma. Mice vaccinated with VSV.gp100 showed robust pmel-1 T cell numbers in blood and efficient accumulation in tumors ( Fig. 1d) . Notably, in mice receiving both VSV. gp100 and gp100.IFA vaccination, we also found pmel-1 T cells in the circulation, but they accumulated largely at gp100/IFA vaccination sites and only slightly at the tumor site ( Fig. 1d ). T cell localization to the gp100/IFA vaccination site and the VdLN was dependent on the presence of cognate gp100 antigen, as it did not occur at antigenfree control sites injected with saline in IFA (control/IFA) ( Fig. 1e) . Flow cytometric evaluation of B16 tumor-bearing mice receiving naive pmel-1 T cells and gp100/IFA vaccination gave similar results ( Supplementary Fig. 5 ).
As T cell accumulation at vaccination sites was antigen driven ( Fig. 1e) , we examined how long gp100/IFA vaccine depots could exert this effect. Pmel-1 effector T cells preferentially accumulated at fresh and 30-day-old gp100/IFA vaccine depots compared to palpable B16 tumors or antigen-negative control/IFA depots ( Fig. 2a) . We found persistent local peptide presentation 11, 12, 15 in the VdLN but not the spleen 30 d after gp100/IFA vaccination ( Fig. 2b) . Notably, 96-day-old gp100/IFA vaccine depots were still able to induce the expansion of freshly injected naive pmel-1 T cells ( Fig. 2c) . Similarly, the HLA-A0201-binding human gp100 209-217(210M) peptide emulsified in clinical-grade IFA (Montanide ISA-51 VG), which is commonly used to vaccinate patients with melanoma 1,6 , was persistently presented on APCs in the VdLN of HLA-A0201 transgenic mice ( Supplementary Fig. 6 ).
T cell apoptosis at vaccination sites driven by IFN-g and FasL
We next determined whether vaccination-induced T cell hyporesponsiveness was due to the prolonged interaction between pmel-1 T cells and persistent gp100 peptide at the vaccination site. Pmel-1 npg T cells, which productively interacted with gp100/IFA for only 48 h, expanded in response to subsequent vaccination, whereas pmel-1 T cells exposed to gp100/IFA for 5 d (Supplementary Fig. 7 ) or 30 d ( Fig. 3a ) did not. Vaccination-induced hyporesponsiveness correlated with increased apoptotic death of pmel-1 T cells isolated from the cutaneous gp100/IFA injection site or VdLN (Fig. 3b) . After transfer of mixed OT-I and pmel-1 effector T cells, we observed a >15-fold increase in apoptotic death in pmel-1 T cells compared to their OT-I counterparts at gp100/IFA vaccination sites ( Supplementary Fig. 8 ),
suggesting that T cell apoptosis required TCR engagement. To investigate the role of TCR signaling strength on T cell deletion 23, 24 , we transferred OT-I T cells into mice and vaccinated them with the cognate OT-I ligand, SIINFEKL, or the altered ligand, SIITFEKL, which has similar binding to H-2K b MHC class I molecules but has a much lower affinity for the OT-I TCR 25 . SIINFEKL-primed OT-I T cells expanded faster and to greater numbers than SIITFEKL-primed OT-I T cells, as has been reported 25 , but apoptotic death rates at both vaccination sites were similar ( Supplementary Fig. 9a,b) . npg Expression of the death receptor, Fas (also called CD95) 26 , was increased on the surface of pmel-1 T cells at the gp100/IFA vaccination site but not in spleen or blood (Fig. 3c) . In mice deficient in Fas ligand (FasL, also called CD95L), pmel-1 T cell apoptosis at the gp100/IFA vaccination sites was reduced (Fig. 3d) . Because IFN-γ is a known inducer of Fas, FasL and T cell apoptosis 27 , we examined its role in apoptosis of T cells at the vaccination site. Endogenous, OVAspecific CD8 + T cells in IFN-γ-deficient mice vaccinated with OVA in IFA (OVA/IFA) showed decreased Fas expression and T cell apoptosis and increased T cell numbers at the vaccination site ( Fig. 3e,f) . Host cells that could mediate T cell death induced by IFN-γ, Fas and FasL include immunoregulatory myeloid cells 28 . At gp100/IFA vaccination sites, IFN-γ promoted the accumulation of CD11b + Gr-1 hi Ly6C int cells resembling granulocytic myeloid derived suppressor cells (MDSCs) and of CD11b + Gr-1 int Ly6C hi cells resembling monocytic MDSCs, the latter of which was recently reported as particularly immunosuppressive in spleens from tumor-bearing hosts 29 (Supplementary Fig. 10a ). The latter cell subset also showed marked IFN-γ-driven upregulation of FasL and the immunosuppressive programmed cell death 1 (PD-1) ligand, PD-L1 ( Supplementary Fig. 10a,b) . Together with the reported near-complete recruitment of the systemic antigen-specific T cell pool to sites of vaccination 30 , these data suggest that gp100/IFA vaccination induced antigen-driven recruitment of the majority of the gp100-specific T cells to the VdLN and vaccination site, where they underwent priming and then antigen-driven apoptosis mediated by IFN-γ and FasL in a T cell-hostile environment replete with myeloid cells expressing FasL and PD-L1.
Short-lived vaccine induces strong T cell responses
As limiting the exposure of pmel-1 T cells to gp100/IFA vaccine depots rescued them from apoptosis, we tested the reverse, more clinically applicable approach of limiting the persistence of vaccine depots. Replacing poorly biodegradable IFA with saline (gp100/saline) abolished gp100 peptide presentation in the VdLN within 7 d after vaccination with gp100/saline ( Fig. 4a) but also abolished pmel-1 T cell priming (Fig. 4b) . We then added three immunostimulatory molecules, hereafter together referred to as covax, that are known to enhance peptide vaccination by licensing and activating APCs npg (CD40-specific monoclonal antibody (mAb) 31, 32 and the TLR7 agonist imiquimod 33, 34 ) and directly supporting primed CD8 + T cells (IL-2) 17, 35 . Vaccination with gp100/saline and covax (gp100/saline/ covax) induced strong, pmel-1 T cell expansion that could be further boosted without hyporesponsiveness (Fig. 4b,c) . Addition of covax induced marked T cell persistence after gp100/ IFA and gp100/saline vaccination; however, post-peak apoptosis and contraction were still stronger after IFA compared to saline-based vaccination ( Fig. 4c,d) . Saline-based vaccination induced higher expression of CD127 (also called IL-7Rα) and its downstream prosurvival molecules B-cell CLL/lymphoma 2 (Bcl-2) and B-cell lymphomaextra large (Bcl-xL) [36] [37] [38] (Fig. 4e) . Even after the addition of covax, antigen presentation in the VdLN after saline-based vaccination almost vanished by 6 d, whereas antigen presentation after IFA-based vaccination actually increased over time (Supplementary Fig. 11 ).
Short-lived vaccine promotes T cell localization to tumor
Whereas gp100/IFA/covax and gp100/saline/covax both induced high numbers of pmel-1 T cells in the blood, suppression of melanoma growth was stronger after vaccination with gp100/saline/covax (Fig. 4f) . We found similar results after therapy of established, palpable melanomas (Fig. 4g) and after priming with VSV.gp100 and boosting with gp100/saline/covax compared to gp100/IFA/covax (Supplementary Fig. 12 ). Saline-based vaccination induced preferential T cell localization and tissue destruction at the tumor site, whereas IFA-based vaccination induced the reverse pattern of T cell sequestration, local tissue destruction and killing of normal gp100 + pigment cells (vitiligo) at the vaccination site (Fig. 5a,b and Supplementary  Fig. 13 ). We obtained similar results with OVA antigen, a model for nonself antigens such as viral and mutated gene products 3, 39 ( Supplementary Fig. 14) . As a recent clinical trial 3 showed promising therapeutic activity of IFA-based vaccines containing longer peptides in IFA, we compared antigen presentation, T cell responses, sequestration and antitumor activity after vaccination with a short (9 residues) and a long (20 residues) gp100 peptide in IFA. Compared to the short peptide, the long peptide induced minimal T cell sequestration at the vaccination site, no rapid contraction of the T cell response and superior antitumor activity (Supplementary Fig. 15a-c) . The long gp100 peptide was presented by relatively rare dendritic cells in the VdLN only, whereas the short gp100 peptide was presented by multiple VdLN cell types, including ubiquitous B cells ( Supplementary  Fig. 15d ). Because long peptides require trimming by dendritic cellspecific intracellular enzymes to allow efficient binding to MHC class I molecules 15 , the resulting dendritic cell-specific antigen presentation may have reduced the intensity of local chronic antigen presentation and the consequent T cell sequestration and deletion.
As chemokines mediate T cell localization 40 , we studied chemokines at vaccination sites and tumors. Chemokine (C-X-C motif) receptor 3 (CXCR3) and its ligands, CXCL9 and CXCL10, are dominant drivers of CD8 + effector T cell trafficking, and effector pmel-1 T cells from vaccinated mice had high expression of CXCR3 (Fig. 5c) . CXCL9 and CXCL10 were present at gp100/IFA but not gp100/saline vaccination sites and at tumor sites 6 d after vaccination (Fig. 5d) . We also detected IFN-γ, a major inducer of CXCL9 and CXCL10, at the gp100/IFA but not at the saline/IFA or gp100/saline vaccination sites, suggesting it was produced by pmel-1 T cells in response to persistent gp100 peptide (Fig. 5d) . Notably, the gp100/IFA vaccination site also uniquely contained IL-1β, IL-6 and IL-17. The presence of IL-17, which was produced in part by pmel-1 T cells at the vaccination site, suggests the induction of a local T helper type 17 npg (T H 17)-like immune response that was, however, not detected at the tumor site ( Fig. 5d and Supplementary Fig. 16 ).
Short-lived vaccine prevents T cell dysfunction
We used gene expression profiling to determine whether persistent gp100 antigen affected pmel-1 T cell function as observed in settings of chronic viral infection and cancer [41] [42] [43] . Compared to gp100/saline/ covax, gp100/IFA/covax induced stronger upregulation of genes associated with proliferation, apoptosis, effector differentiation and memory formation, and T cell exhaustion and tolerance ( Fig. 6a,  Supplementary Fig. 17 and Supplementary Results) . Gp100/IFA/ covax-primed pmel-1 T cells in blood showed upregulation of inhibitory receptors PD-1 and, to a lesser extent, lymphocyte activation gene 3 (LAG-3) and hepatitis A virus cellular receptor 2 (Tim-3, also called HAVCR2) during the first 21 d (Fig. 6b) . At the vaccination site, gp100/IFA/covax induced higher, antigen-driven expression of inhibitory receptors PD-1, LAG-3, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and Tim-3 ( Fig. 6c and Supplementary Fig. 8 ) and dysfunction as measured by decreased IFN-γ and TNF-α production, suggestive of partial exhaustion (Fig. 6c) 42, 44 . Gp100/saline vaccine favored the early induction of a killer cell lectin-like receptor G1 (KLRG-1) hi CD127 hi Bcl-2 hi effector T cell phenotype 44 (Figs. 4e and  6b) , which gradually shifted towards a KLRG-1 lo CD127 hi Bcl-2 hi memory T cell phenotype (Supplementary Fig. 18 ). Eventually (day 80), remaining gp100/IFA-primed pmel-1 T cells showed a predominant effector memory phenotype (CD127 hi /CD62L lo ), whereas gp100/saline-primed cells mostly showed a central memory phenotype (CD127 hi /CD62L hi ) (Supplementary Fig. 19) . Altogether, persistent antigen at vaccination sites induced priming of tumor-specific T cells followed by their sequestration, dysfunction and deletion. Strong proimmunogenic signals could partially overcome T cell deletion, but could not overcome local antigen-driven chemokine induction, T cell sequestration and dysfunction and tissue destruction at vaccination sites. In contrast, a short-lived vaccine formulation induced long-lived, functional T cells that localized preferentially to tumor sites, increasing antitumor activity.
DISCUSSION
We found that persistent gp100/IFA vaccine depots induced priming of tumor-specific CD8 + T cells, which accumulated at the vaccination site, preventing their tumor localization while causing their dysfunction and deletion. Different peptides in IFA show different pharmacokinetics and in vivo distribution 13, 14, 45, 46 . We found prolonged local release from IFA depots of the three peptides examined in this study: H-2D b -restricted mouse heteroclitic (h)gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] , H-2K brestricted chicken ovalbumin 257-264 and HLA-A*0201-restricted human (h)gp100 209-217(210M) . Clinical observations suggest that sequestration and deletion of primed T cells can also occur in patients with cancer vaccinated with minimal determinant peptides in IFA.
Tumor-specific CD8 + T cells were deleted after vaccination of patients with cancer with leukemia antigen-derived Wilms tumor 1 (WT-1) and PR1 peptides in IFA 47 . Vaccination of patients with melanoma with heteroclitic melanoma associated antigen recognized by T cells 1 (MART-1) peptide in IFA combined with the TLR9 agonist, CpG (MART-1/IFA/CpG), induced re-inflammation of distant, old MART-1/IFA/CpG vaccination sites, poor tumor localization and no tumor regression 48, 49 . Similar inflammation of old vaccination sites after revaccination was observed in patients with cervical cancer vaccinated with human papilloma virus (HPV) peptides in IFA 50 and in patients with colorectal 51 and ovarian 52 cancer vaccinated with p53-derived peptides in IFA. The latter study also showed specific T cell accumulation at vaccination sites and no tumor regression. In addition, patients vaccinated with multiple melanoma-derived peptides in IFA experienced an accumulation of primed CD8 + T cells in VdLN that exceeded accumulation at tumor sites and no tumor regression 53, 54 . We speculate that in this series of clinical trials, low numbers of T cells surviving earlier vaccination expanded as a result of revaccination and preferentially localized to and inflamed both new and old, persisting, peptide-rich vaccination sites rather than tumor sites. A limitation of our animal model is the difference in body size between a mouse and human relative to antigen dose and vaccine depot size. We never found a gp100 peptide dose that was 'just right' to induce priming without subsequent T cell deletion. As persistent gp100 antigen presentation was restricted to the vaccination site and VdLN, body size does not seem to be a major confounding factor in this study.
Notably, our data indicate that vaccination with peptide in IFA is superior to no vaccination, as some primed T cells still reach the tumor site. A recent randomized phase 3 study 1 showed modest but npg real clinical benefit of peptide vaccination when added to high-dose IL-2 therapy, possibly because IL-2 induces systemic cytokine release that can activate APCs and support vaccine-primed T cell survival, similarly to covax in our study. However, our findings suggest that the full therapeutic power of current IFA-based vaccine therapy may not be realized due to vaccination-site sequestration, dysfunction and deletion of most primed T cells. In one study, vaccination with gp100 209-217(210M) peptide in IFA raised gp100-specific CD8 + T cell numbers to >1% of peripheral CD8 + T cells in the majority of patients with melanoma, although this required up to 64 vaccinations over 48 weeks 6 . Again, gp100-specific CD8 + T cell concentrations in blood did not predict clinical benefit, whereas substantial local vaccination site toxicity was observed that caused 17% of vaccinated patients to withdraw from the study 6 . Interestingly, a recent trial of vaccination of healthy volunteers with HIV-derived peptides in IFA had to be discontinued because of ulcerating sterile inflammation and abscesses at vaccination sites that increased in severity with the intensity of the induced specific T cell response 55 . We propose that IFA-based vaccination turns the vaccination site into a persistent source of T cell priming as well as a target tissue in a positive feedback loop whereby T cells are primed in the VdLN, exit into the blood where they are detectable by immune monitoring assays, then re-enter the inflamed vaccination site and VdLN, where they respond to vaccine-derived peptide with cytotoxic killing, chemokine and cytokine production, dysfunction and apoptosis. Peptide/ IFA vaccination sites contain supraphysiological amounts of antigen: 1 mg/ml (~1 mM) of nonamer peptide in our animal model and in many human cancer vaccine trials. Moreover, these peptides are often optimized, and therefore they are more immunogenic variants of the native peptides that are produced and presented by tumor cells. Thus, peptide/IFA-based vaccination sites may outcompete tumor sites for T cell recognition, chemokine production, T cell accumulation and tissue destruction.
In summary, our findings may help explain the typically limited clinical benefit of antigen-specific CD8 + T cells induced by a widely used class of cancer vaccines. The recognition that persistent antigen at vaccination sites induces strong sequestration and subsequent dysfunction and deletion of vaccination-induced T cells directly points to desired characteristics of new classes of vaccines based on nonpersistent and rapidly biodegradable vaccine adjuvants.
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